Randomized Trialhigh evidence
Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.
JAMA·June 7, 2026·PMID 42251769
Why it mattersOrforglipron is an oral, nonpeptide GLP-1 receptor agonist that can be combined with basal insulin, offering a convenient alternative to injectable GLP-1 agonists for patients needing further glycemic and weight control.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled